Document:

EX-4.3

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 Exhibit 4.3 

REGISTRATION RIGHTS AGREEMENT 
 This
Registration Rights Agreement (this “Agreement”) is made as of [    ], 2020 by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons listed on the
attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to
them in Section 1. 
 RECITALS 

WHEREAS, the Company and the Investors wish to provide for certain arrangements with respect to the registration of the Registrable Securities (as
defined below) by the Company under the Securities Act (as defined below). 
 NOW, THEREFORE, in consideration of the mutual promises and covenants
set forth herein, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

Section 1. 

Definitions 

1.1.    Certain Definitions. In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the following
terms have the respective meanings set forth below: 
 (a)    “Board” shall mean the Board of Directors of the Company.

 (b)    “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act. 
 (c)    “Common Stock” shall mean the voting common stock of the Company, par value
$0.0001 per share. 
 (d)    “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar
successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(e)    “Investors’ Rights Agreement” shall mean the Amended and Restated Investors’ Right Agreement, dated as
of August 21, 2020, by and among the Company and the investors named therein. 
 (f)     “Other Investors” shall
mean the “Investors”, as defined in those certain Registration Rights Agreement, of even date herewith, entered into by and between the Company and each of [    ] (collectively, and without taking into account any
amendments thereto after the date hereof, the “Other RRAs”). 
 (g)    “Other Investors’ Registrable
Securities” means the Registrable Securities (as defined in each of the Other RRAs) of the Other Investors. 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (h)     “Other Securities” shall mean securities of the Company, other
than Registrable Securities or the Other Investors’ Registrable Securities. 
 (i)    “Person” shall mean any
individual, partnership, corporation, company, association, trust, joint venture, limited liability company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof. 

(j)    “Registrable Securities” shall mean the shares of Common Stock and any Common Stock issued or issuable upon the
exercise or conversion of any other securities (whether equity, debt or otherwise) of the Company now owned or hereafter acquired by any of the Investors. Registrable Securities held by any of the Investors shall cease to be Registrable Securities
of the Investors upon the earliest to occur of the following events: (i) such Registrable Securities have been sold pursuant to an effective Registration Statement; (ii) such Registrable Securities have been sold by the Investors pursuant
to Rule 144 (or other similar rule), (iii) such Registrable Securities may be resold by the Investor holding such Registrable Securities without limitations as to volume or manner of sale pursuant to Rule 144; or (iv) ten (10) years after the
date of this Agreement. For purposes of this definition, in order to determine whether an Investor is an “affiliate” (as such term is defined and used in Rule 144, and including for determining whether volume or manner of sale limitations
of Rule 144 apply) the parties will assume that all convertible securities (whether equity, debt or otherwise) have been converted into Common Stock without regard to any limitations on conversion applicable thereto. 

(k)    The terms “register,” “registered” and “registration” shall refer to a
registration effected by preparing and filing a Registration Statement in compliance with the Securities Act, and such Registration Statement becoming effective under the Securities Act. 

(l)    “Registration Expenses” shall mean all expenses incurred by the Company in effecting any registration pursuant to
this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, up to $50,000 of reasonable legal expenses of one special counsel for
Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) in connection with the preparation and filing of the Resale Registration Shelf, and up to $50,000 of reasonable legal expenses of one
special counsel for Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) per underwritten public offering, blue sky fees and expenses, and expenses of any regular or special audits
incident to or required by any such registration, but shall not include Selling Expenses. 
 (m)    “Registration
Statement” means any registration statement of the Company filed with, or to be filed with, the Commission under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws other than a registration
statement (and related prospectus) filed on Form S-4 or Form S-8 or any successor forms thereto. 

(n)    “Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such rule may be
amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

  
 2 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (o)    “Securities Act” shall mean the Securities Act of 1933, as
amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(p)    “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of
Registrable Securities, the fees and expenses of any legal counsel (except as provided in the definition of “Registration Expenses”) and any other advisors any of the Investors engage and all similar fees and commissions relating to the
Investors’ disposition of the Registrable Securities. 
 Section 2. 

Resale Registration Rights 

2.1.    Resale Registration Rights. 

(a)    Following demand by any Investor, the Company shall file with the Commission a Registration Statement on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance with the Securities Act) covering the resale of the Registrable Securities by the Investors (the “Resale Registration Shelf”), and the Company shall file such Resale Registration Shelf as promptly as reasonably
practicable following such demand, and in any event within sixty (60) days of such demand. Such Resale Registration Shelf shall include a “final” prospectus, including the information required by Item 507 of Regulation S-K of the Securities Act, as provided by the Investors in accordance with Section 2.7. Notwithstanding the foregoing, before filing the Resale Registration Shelf, the Company shall furnish to the Investors a
copy of the Resale Registration Shelf and afford the Investors an opportunity to review and comment on the Resale Registration Shelf. The Company’s obligation pursuant to this Section 2.1(a) is conditioned upon the
Investors providing the information contemplated in Section 2.7. 
 (b)    The Company shall use its
reasonable best efforts to cause the Resale Registration Shelf and related prospectuses to become effective as promptly as practicable after filing. The Company shall use its reasonable best efforts to cause such Registration Statement to remain
effective under the Securities Act until the earlier of the date (i) all Registrable Securities covered by the Resale Registration Shelf have been sold or (ii) all Registrable Securities covered by the Resale Registration Shelf otherwise
cease to be Registrable Securities. The Company shall promptly, and within two (2) business days after the Company confirms effectiveness of the Resale Registration Shelf with the Commission, notify the Investors of the effectiveness of the
Resale Registration Shelf. 
 (c)    Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to
effect, or to take any action to effect, a registration pursuant to Section 2.1(a): 
 (i)    if the Company
has and maintains an effective Registration Statement on Form S-3ASR that provides for the resale of an unlimited number of securities by selling stockholders (a “Company Registration Shelf”);

 (ii)    during the period forty-five (45) days prior to the Company’s good faith estimate of the date of filing of a
Company Registration Shelf; or 

  
 3 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (iii)    if the Company has caused a Registration Statement to become effective
(A) pursuant to this Section 2.1 or (B) Section 2.1 of any of the Other RRAs (and complied with its obligations under Section 2.1(f), below, in connection therewith) during the prior
twelve (12) month period. 
 (d)    If the Company has a Company Registration Shelf in place at any time in which the Investors
make a demand pursuant to Section 2.1(a), the Company shall file with the Commission, as promptly as practicable, and in any event within fifteen (15) business days after such demand, a “final” prospectus
supplement to its Company Registration Shelf covering the resale of the Registrable Securities by the Investors (the “Prospectus”); provided, however, that the Company shall not be obligated to file more than one
Prospectus pursuant to this Section 2.1(d) in any six month period to add additional Registrable Securities to the Company Registration Shelf that were acquired by the Investors other than directly from the Company or in an
underwritten public offering by the Company. The Prospectus shall include the information required under Item 507 of Regulation S-K of the Securities Act, which information shall be provided by the Investors
in accordance with Section 2.7. Notwithstanding the foregoing, before filing the Prospectus, the Company shall furnish to the Investors a copy of the Prospectus and afford the Investors an opportunity to review and comment
on the Prospectus. 
 (e)    Deferral and Suspension. At any time after being obligated to file a Resale Registration Shelf or
Prospectus, or after any Resale Registration Shelf has become effective or a Prospectus is filed with the Commission (in each case, including pursuant to an Other RRA), the Company may defer the filing of or suspend the use of any such Resale
Registration Shelf or Prospectus, upon giving written notice of such action to the Investors with a certificate signed by the Principal Executive Officer of the Company stating that in the good faith judgment of the Board, the filing or use of any
such Resale Registration Shelf or Prospectus covering the Registrable Securities would be seriously detrimental to the Company or its stockholders at such time and that the Board concludes, as a result, that it is in the best interests of the
Company and its stockholders to defer the filing or suspend the use of such Resale Registration Shelf or Prospectus at such time. The Company shall have the right to defer the filing of or suspend the use of such Resale Registration Shelf or
Prospectus for a period of not more than one hundred twenty (120) days from the date the Company notifies the Investors of such deferral or suspension; provided that the Company shall not exercise the right contained in this
Section 2.1(e) more than once in any twelve month period. In the case of the suspension of use of any effective Resale Registration Shelf or Prospectus, the Investors, immediately upon receipt of notice thereof from the
Company, shall discontinue any offers or sales of Registrable Securities pursuant to such Resale Registration Shelf or Prospectus until advised in writing by the Company that the use of such Resale Registration Shelf or Prospectus may be resumed. In
the case of a deferred Prospectus or Resale Registration Shelf filing, the Company shall provide prompt written notice to the Investors of (i) the Company’s decision to file or seek effectiveness of the Prospectus or Resale Registration
Shelf, as the case may be, following such deferral and (ii) in the case of a Resale Registration Shelf, the effectiveness of such Resale Registration Shelf. In the case of either a suspension of use of, or deferred filing of, any Resale
Registration Shelf or Prospectus, the Company shall not, during the pendency of such suspension or deferral, be required to take any action hereunder (including any action pursuant to Section 2.2 hereof) with respect to the
registration or sale of any Registrable Securities pursuant to any such Resale Registration Shelf, Company Registration Shelf or Prospectus. 

  
 4 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (f)    Piggy-Back Rights. The Company must provide the Investors with ten
(10) days’ notice before filing any Resale Registration Shelf or Prospectus pursuant to a request by the Other Investors pursuant to Section 2.1(a) of the Other RRAs, and, upon the Investors’ written request,
include the Investors as one or more selling stockholders in such Resale Registration Shelf or Prospectus. Section 2.1(g) of the Other RRAs notwithstanding, the securities of the Investors and the Other Investors will be
excluded on a pro rata basis from such Registration Statement if any such exclusion is deemed necessary in order to comply with any applicable laws or request from the Commission, Nasdaq or any applicable listing agency. 

(g)    Other Securities. Any Resale Registration Shelf or Prospectus may include Other Investors’ Registrable Securities,
Other Securities, and may include securities of the Company being sold for the account of the Company; provided (i) such Other Investors’ Registrable Securities are treated in a manner consistent with Section 2.1(f) of the
Other RRAs) and (ii) such Other Securities are excluded first from such Registration Statement in order to comply with any applicable laws or request from the Commission, Nasdaq or any applicable listing agency. For the avoidance of doubt, no
Other Securities may be included in an underwritten offering pursuant to Section 2.2 without the consent of the Investors except as expressly set forth herein. 

2.2.    Sales and Underwritten Offerings of the Registrable Securities. 

(a)    Notwithstanding any provision contained herein to the contrary, the Investors, collectively, shall and subject to the limitations
set forth in this Section 2.2, be entitled to demand up to two underwritten public offerings to effect the sale or distribution of Registrable Securities during the term of this Agreement; provided that the Investors and
the Other Investors shall be entitled to not more than an aggregate of two underwritten public offerings per calendar year pursuant to this Section 2.2 or Section 2.2 of the Other RRAs. 

(b)    If the Investors intend to effect an underwritten public offering pursuant to a Resale Registration Shelf or Company Registration
Shelf to sell or otherwise distribute Registrable Securities, they shall so advise the Company and provide as much notice to the Company as reasonably practicable (and in any event not less than fifteen (15) business days prior to the
Investors’ request that the Company file a prospectus supplement to a Resale Registration Shelf or Company Registration Shelf). 

(c)    In connection with any offering initiated by the Investors pursuant to this Section 2.2 involving an
underwriting of shares of Registrable Securities, the Investors shall be entitled to select the underwriter or underwriters for such offering, subject to the consent of the Company, such consent not to be unreasonably withheld, conditioned or
delayed. 
 (d)    In connection with any offering initiated by the Investors pursuant to this Section 2.2
involving an underwriting of shares of Registrable Securities, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Investors (i) enter into an underwriting agreement in customary
form with the underwriter or underwriters, (ii) accept customary terms in such underwriting agreement with regard to representations and warranties relating to ownership of the Registrable Securities and authority and power to enter into such
underwriting agreement and (iii) complete and execute all questionnaires, powers of attorney, custody agreements, indemnities and other documents as may be requested by such 

  
 5 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 
underwriter or underwriters. Further, the Company shall not be required to include any of the Registrable Securities in such underwriting if (Y) the underwriting agreement proposed by the
underwriter or underwriters contains representations, warranties or conditions that are not reasonable in light of the Company’s then-current business or (Z) the underwriter, underwriters or the Investors require the Company to participate
in any marketing, road show or comparable activity that may be required to complete the orderly sale of shares by the underwriter or underwriters. 

(e)    Subject to Section 2.2(f) below, the Company must provide the Investors with not less than ten
(10) business days’ notice before effecting an underwritten public offering of Other Investors’ Registrable Securities (including pursuant to Section 2.2 of the Other RRAs) and Other Securities, and, upon the
Investor’s written request, include the Registrable Securities requested by Investor in such underwritten public offering. 

(f)    If the total amount of securities to be sold in any underwritten public offering initiated by the Investors pursuant to this
Section 2.2, or any underwritten public offering initiated by the Other Investors pursuant to their registration rights, exceeds the amount that the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities (subject in each case to the cutback provisions set forth in this
Section 2.2(f)), that the underwriters and the Company determine in their sole discretion shall not jeopardize the success of the offering. If the underwritten public offering has been requested pursuant to
Section 2.2(a) of this Agreement or the Other RRAs, the number of shares that are entitled to be included in the registration and underwriting shall be allocated in the following manner: (a) first, shares of
Company equity securities that the Company desires to include in such registration shall be excluded and (b) second, Registrable Securities requested to be included in such registration by the Investors and the Other Investors shall be
excluded, pro rata. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round down the number of shares allocated to any of the Investors or the Other Investors to the nearest
100 shares. 
 2.3.    Fees and Expenses. All Registration Expenses incurred in connection with registrations pursuant to this
Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors. 

2.4.    Registration Procedures. In the case of each registration of Registrable Securities effected by the Company pursuant to
Section 2.1 hereof (including, for the avoidance of doubt, Section 2.1(f)), the Company shall keep the Investors advised as to the initiation of each such registration and as to the status thereof.
The Company shall use its reasonable best efforts, within the limits set forth in this Section 2.4, to: 

(a)    prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectuses used in
connection with such Registration Statement as may be necessary to keep such Registration Statement effective and current and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such
Registration Statement; 

  
 6 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (b)    furnish to the Investors such numbers of copies of a prospectus, including
preliminary prospectuses, in conformity with the requirements of the Securities Act, and such other documents as the Investors may reasonably request in order to facilitate the disposition of Registrable Securities; 

(c)    use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under
such other securities or blue sky laws of such jurisdictions in the United States as shall be reasonably requested by the Investors, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions; 
 (d)    in the event of any
underwritten public offering, and subject to Section 2.2(d), enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering and take such
other usual and customary action as the Investors may reasonably request in order to facilitate the disposition of such Registrable Securities; 

(e)    notify the Investors at any time when a prospectus relating to a Registration Statement covering any Registrable Securities is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company shall use its reasonable best efforts to amend or supplement such prospectus in order
to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then
existing; 
 (f)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to such Registration
Statement and, if required, a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(g)    if requested by an Investor, use reasonable best efforts to cause the Company’s transfer agent to remove any restrictive
legend from any Registrable Securities, within two business days following such request; 
 (h)    cause to be furnished, at the request
of the Investors, on the date that Registrable Securities are delivered to underwriters for sale in connection with an underwritten offering pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company
for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter or letters from the independent certified public
accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; and 

  
 7 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 (i)    cause all such Registrable Securities included in a Registration Statement
pursuant to this Agreement to be listed on each securities exchange or other securities trading markets on which Common Stock is then listed. 

2.5.    The Investors Obligations. 

(a)    Discontinuance of Distribution. The Investors agree that, upon receipt of any notice from the Company of the occurrence of
any event of the kind described in Section 2.4(e) hereof, the Investors shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until
the Investors’ receipt of the copies of the supplemented or amended prospectus contemplated by Section 2.4(e) hereof or receipt of notice that no supplement or amendment is required and that the Investors’
disposition of the Registrable Securities may be resumed. The Company may provide appropriate stop orders to enforce the provisions of this Section 2.5(a). 

(b)    Compliance with Prospectus Delivery Requirements. The Investors covenant and agree that they shall comply with the
prospectus delivery requirements of the Securities Act as applicable to them or an exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement filed by the Company pursuant to this Agreement. 

(c)    Notification of Sale of Registrable Securities. The Investors covenant and agree that they shall notify the Company
following the sale of Registrable Securities to a third party as promptly as reasonably practicable, and in any event within thirty (30) days, following the sale of such Registrable Securities. 

2.6.    Indemnification. 

(a)    To the extent permitted by law, the Company shall indemnify the Investors, and, as applicable, their officers, directors, and
constituent partners, legal counsel for each Investor and each Person controlling the Investors, with respect to which registration, related qualification, or related compliance of Registrable Securities has been effected pursuant to this Agreement,
and each underwriter, if any, and each Person who controls any underwriter within the meaning of the Securities Act against all claims, losses, damages, or liabilities (or actions in respect thereof) to the extent such claims, losses, damages, or
liabilities arise out of or are based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such registration,
qualification, or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation
by the Company of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to the Company and relating to action or
inaction required of the Company in connection with any such registration, qualification, or compliance; and the Company shall pay as incurred to the Investors, each such underwriter, and each Person who controls the Investors or underwriter, any
legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action; provided, however, that the indemnity contained in this
Section 2.6(a) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if 

  
 8 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 
settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided, further, that the Company shall not be liable in any such case to the
extent that any such claim, loss, damage, liability, or expense arises out of or is based upon any violation by such Investor of the obligations set forth in Section 2.5 hereof or any untrue statement or omission contained
in such prospectus or other document based upon written information furnished to the Company by the Investors, such underwriter, or such controlling Person and stated to be for use therein. 

(b)    To the extent permitted by law, each Investor (severally and not jointly) shall, if Registrable Securities held by such Investor
are included for sale in the registration and related qualification and compliance effected pursuant to this Agreement, indemnify the Company, each of its directors, each officer of the Company who signs the applicable Registration Statement, each
legal counsel and each underwriter of the Company’s securities covered by such a Registration Statement, each Person who controls the Company or such underwriter within the meaning of the Securities Act against all claims, losses, damages, and
liabilities (or actions in respect thereof) arising out of or based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, or related document, or (ii) any omission (or
alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by such Investor of Section 2.5
hereof, the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to such Investor and relating to action or inaction
required of such Investor in connection with any such registration and related qualification and compliance, and shall pay as incurred to such persons, any legal and any other expenses reasonably incurred in connection with investigating or
defending any such claim, loss, damage, liability, or action, in each case only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in (and such violation pertains to) such Registration
Statement or related document in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use therein; provided, however, that the indemnity contained in this
Section 2.6(b) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of such Investor (which consent shall not unreasonably be
withheld); provided, further, that such Investor’s liability under this Section 2.6(b) (when combined with any amounts such Investor is liable for under Section 2.6(d)) shall not exceed
such Investor’s net proceeds from the offering of securities made in connection with such registration. 
 (c)    Promptly after
receipt by an indemnified party under this Section 2.6 of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this
Section 2.6, notify the indemnifying party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim;
provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld; provided
further, however, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for
indemnity under 

  
 9 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 
this Section 2.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the
interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent
so prejudiced, of any liability to the indemnified party under this Section 2.6, but the omission so to notify the indemnifying party shall not relieve such party of any liability that such party may have to any indemnified
party otherwise than under this Section 2.6. 
 (d)    If the indemnification provided for in this
Section 2.6 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. In no event,
however, shall (i) any amount due for contribution hereunder be in excess of the amount that would otherwise be due under Section 2.6(a) or Section 2.6(b), as applicable, based on the
limitations of such provisions and (ii) a Person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) be entitled to contribution from a Person who was not guilty of such fraudulent misrepresentation. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided, however, that the failure of the
underwriting agreement to provide for or address a matter provided for or addressed by the foregoing provisions shall not be a conflict between the underwriting agreement and the foregoing provisions. 

(f)    The obligations of the Company and the Investors under this Section 2.6 shall survive the completion of
any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 2.7.    Information. The
Investors shall furnish to the Company such information regarding the Investors and the distribution proposed by the Investors as the Company may reasonably request and as shall be reasonably required in connection with any registration referred to
in this Agreement. The Investors agree to, as promptly as practicable (and in any event prior to any sales made pursuant to a prospectus), furnish to the Company all information required to be disclosed in order to make the information previously
furnished to the Company by the Investors not misleading. The Investors agree to keep confidential the receipt of any notice received 

  
 10 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 
pursuant to Section 2.4(e) and the contents thereof, except as required pursuant to applicable law. Notwithstanding anything to the contrary herein, the Company shall be
under no obligation to name the Investors in any Registration Statement if the Investors have not provided the information required by this Section 2.7 with respect to the Investors as a selling securityholder in such
Registration Statement or any related prospectus. 
 2.8.    Rule 144 Requirements. With a view to making available to the
Investors the benefits of Rule 144 and any other rule or regulation of the Commission that may at any time permit the Investors to sell Registrable Securities to the public without registration, the Company agrees to use its reasonable best efforts
to: 
 (a)    make and keep public information available, as those terms are understood and defined in Rule 144 at all times after the
date hereof; 
 (b)    file with the Commission in a timely manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act; 
 (c)    prior to the filing of the Registration Statement or any amendment thereto (whether pre-effective or post-effective), and prior to the filing of any prospectus or prospectus supplement related thereto, to provide the Investors with copies of all of the pages
thereof (if any) that reference the Investors; and 
 (d)    furnish to any Investor, so long as the Investor owns any Registrable
Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and
documents so filed by the Company, and (iii) such other information as may be reasonably requested by an Investor in availing itself of any rule or regulation of the Commission which permits an Investor to sell any such securities without
registration. 
 2.9.    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company
shall not, without prior written consent of the Investors, (a) enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such holder rights with respect to the registration of such
securities under the Securities Act or the Exchange Act that would conflict with or adversely affect any of the rights provided to the Investors in this Section 2, or (b) amend the registration rights provisions of the
Investors’ Rights Agreement or any of the Other RRAs in any manner that would conflict with or adversely affect any of the rights provided to the Investors in this Section 2 (and, in the case of any such amendment, the
Company shall notify the Investors in advance of such amendment for it to determine whether such amendment would conflict with or adversely affects their rights in this Section 2); it being understood and agreed that any subsequent agreement of
the Company with any holder or prospective holder of any securities of the Company of the same class (or convertible into or exchange for securities of the same class) as the Registrable Securities that grants rights equivalent to the rights of the
Investors under this Section 2 will not be prohibited by the terms of this Section 2.9 so long as the inclusion of such holder or prospective holder’s securities will not reduce the number of
the Registrable Securities of the Holders that are included in any registration hereunder or thereunder. 

  
 11 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 Section 3. 

Miscellaneous 

3.1.    Amendment. No amendment, alteration or modification of any of the provisions of this Agreement shall be binding unless made
in writing and signed by each of the Company and the Investors. 
 3.2.    Injunctive Relief. It is hereby agreed and
acknowledged that it shall be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person shall be
irreparably damaged and shall not have an adequate remedy at law. Any such Person shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation,
specific performance, to enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law. 

3.3.    Notices. All notices required or permitted under this Agreement must be in writing and sent to the address or facsimile
number identified below. Notices must be given: (a) by personal delivery, with receipt acknowledged; (b) by facsimile followed by hard copy delivered by the methods under clause (c) or (d); (c) by prepaid certified or
registered mail, return receipt requested; or (d) by prepaid reputable overnight delivery service. Notices shall be effective upon receipt. Either party may change its notice address by providing the other party written notice of such change.
Notices shall be delivered as follows: 
  

			
	If to the Investors:	  	At such Investor’s address as set forth on Schedule A hereto
		
	If to the Company:	  	 200 Powder Mill Road, Wilmington, DE 19803

Attention: Chief Executive Officer

		
	with a copy to:	  	 Fenwick & West LLP
 Attention: Robert
Freedman
 555 California Street, 12th Floor

San Francisco, CA 94109
 Email:
rfreedman@fenwick.com

 3.4.    Governing Law; Jurisdiction; Venue; Jury Trial. 

(a)    This Agreement shall be governed by, and construed in accordance with, the law of the State of New York without giving effect to any
choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. 

(b)    Each of the Company and the Investors irrevocably and unconditionally submits, for itself and its property, to the nonexclusive
jurisdiction of the courts of the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or

  
 12 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 
proceeding arising out of or relating to this Agreement and the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Investors
irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York state court or, to the fullest extent permitted by applicable law, in such federal court. Each of the
Company and the Investors hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

(c)    Each of the Company and the Investors irrevocably and unconditionally waives, to the fullest extent permitted by applicable law,
any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein in any court referred to in
Section 3.4(b) hereof. Each of the Company and the Investors hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding
in any such court. 
 (d)    EACH OF THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH
OF THE COMPANY AND THE INVESTORS (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT EACH OF THE COMPANY AND THE INVESTORS HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

3.5.    Successors, Assigns and Transferees. Any and all rights, duties and obligations hereunder shall not be assigned,
transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party; provided, however, that the Investors shall be entitled to transfer Registrable Securities to one or more of their
affiliates and, solely in connection therewith, may assign their rights hereunder in respect of such transferred Registrable Securities, in each case, so long as such Investor is not relieved of any liability or obligations hereunder, without the
prior consent of the Company. Any transfer or assignment made other than as provided in the first sentence of this Section 3.5 shall be null and void. Subject to the foregoing and except as otherwise provided herein, the
provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. The Company shall not consummate any recapitalization, merger,
consolidation, reorganization or other similar transaction whereby stockholders of the Company receive (either directly, through an exchange, via dividend from the Company or otherwise) equity (the “Other Equity”) in any other
entity (the “Other Entity”) with respect to Registrable Securities hereunder, unless prior to the consummation thereof, the Other Entity assumes, by written instrument, the obligations under this Agreement with respect to such Other
Equity as if such Other Equity were Registrable Securities hereunder. 

  
 13 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 3.6.    Entire Agreement. This Agreement, together with any exhibits hereto,
constitute the entire agreement between the parties relating to the subject matter hereof and all previous agreements or arrangements between the parties, written or oral, relating to the subject matter hereof are superseded. To the extent there is
any conflict between the terms of this Agreement and the terms of the Investors’ Rights Agreement, the terms of this Agreement shall govern. 

3.7.    Waiver. No failure on the part of either party hereto to exercise any power, right, privilege or remedy under this
Agreement, and no delay on the part of either party hereto in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy
shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. 
 3.8.    Severability.
If any part of this Agreement is declared invalid or unenforceable by any court of competent jurisdiction, such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that shall render
such provision valid while preserving the parties’ original intent to the maximum extent possible. 
 3.9.    Titles and
Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall,
unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto. References to any section in an Other RRA shall be deemed to refer to the equivalent section in the event of any amendment thereto. 

3.10.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the
parties that execute such counterparts (including by facsimile or other electronic means), and all of which together shall constitute one instrument. 

3.11.    Term and Termination. The Investors’ rights to demand the registration of the Registrable Securities under this
Agreement, as well as the Company’s obligations hereunder other than pursuant to Section 2.6 hereof, shall terminate automatically once all Registrable Securities cease to be Registrable Securities pursuant to the
terms of this Agreement. 
 [Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 14 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the
day, month and year first above written. 
  

			
	 PRELUDE THERAPEUTICS

INCORPORATED

		
	By:	 	  

	Name:	 	Krishna Vaddi
	Title:	 	Chief Executive Officer

 [Signature Page to Registration Rights Agreement] 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the
day, month and year first above written. 
  

			
	[INVESTOR]
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[INVESTOR]
		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signature Page to Registration Rights Agreement] 

  

 Confidential Treatment Requested by Prelude Therapeutics Incorporated 

Pursuant To 17 C.F.R. Section 200.83 
  

 Schedule A 

The Investors 

[    ]Exhibit 10.1

 

EXECUTION VERSION

 

AMENDMENT NO. 2 TO 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This AMENDMENT No. 2 (this
 “Amendment”) to the executive employment agreement between P&F INDUSTRIES, INC., a Delaware
corporation (the “Company”), and JOSEPH A. MOLINO, JR. (the
 “Executive”) dated as of January 1, 2018 (the “Original Employment Agreement”), as amended
by Amendment No. 1 to the Original Employment Agreement, entered into as of March 5, 2019 (“Amendment No. 1” and the
Original Employment Agreement as amended by Amendment No. 1, the “Employment Agreement”), is being entered into
and is effective as of this 30th day of December, 2020 (the “Amendment Effective Date”).

 

W I T N E S S E T H

 

WHEREAS,
the Company and the Executive are parties to the Employment Agreement; and

 

WHEREAS,
the Company and the Executive desire to amend the terms of the Employment Agreement as provided herein, effective as of the Amendment
Effective Date.

 

NOW,
THEREFORE, in consideration of the mutual promises herein contained and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, effective as of the Amendment Effective Date, the parties hereto hereby agree
as follows:

 

1.     Section 2 of the Employment Agreement is amended by replacing the reference to “December 31, 2020” therein with
 “December 31, 2023”.

 

2.     Except as otherwise set forth in this Amendment, all other terms and conditions of the Employment Agreement shall remain
in full force and effect. Upon execution of this Amendment, each of the undersigned hereby approves, confirms and ratifies the
Employment Agreement as amended by this Amendment. Without limiting the generality of the foregoing, this Amendment shall be subject
to Sections 18 and 21 of the Employment Agreement.

 

3.     This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original and all of
which together shall constitute one and the same instrument. The parties hereto agree to accept a signed facsimile copy of this
Amendment as a fully binding original.

 

(Signature page follows)

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Amendment Effective Date.

 

 

	 	P&F INDUSTRIES, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Richard Horowitz
	 	 	Richard Horowitz
	 	 	Chairman of the Board, President and Chief Executive Officer
	 	 	 
	 	 	 
	 	/s/ Joseph A. Molino, Jr.
	 	JOSEPH A. MOLINO, JR.

 

[Signature Page to Amendment No. 2]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]